Abstract

The overall cost for drugs prescribed in the UK is fixed in negotiations between the Department of Health (DoH) and individual drug companies. New terms for the Pharmaceutical Price Regulation Scheme (PPRS), which govern these negotiations, came into effect in October and will operate till April 1998.¹ In this article we discuss the PPRS itself and consider whether the new terms offer any advance over previous arrangements which we have criticised.^2,3